Liquidia Settles Lawsuit with United Therapeutics for $380.7 Million
1 report, 1 independent
Updated Oct 14
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Liquidia settled all pending lawsuits with United Therapeutics for net payments totaling $380.7 million after the market closed on October 13, 2026. This settlement followed a September 30, 2026 ruling that found asserted patent claims valid and infringed. The agreement permanently removes the 60,000-patient PH-ILD indication from YUTREPIA's label.
From aol.com
Why it matters
The settlement avoids the possibility of YUTREPIA being pulled from the market entirely. However, the payment represents about 16% of Liquidia's $2.40 billion market value, and the deal removes an approved use from the drug.
From aol.com
Who's involved
- United TherapeuticsUnited Therapeutics, the party Liquidia settled with regarding the patent claims.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Liquidia's settlement could reduce Medicare's coverage for YUTREPIAMedicare's coverage scope for YUTREPIA may shrink after drug label change.Likely
- Liquidia settlement requires FDA to update Yutrepia's approved labelThe FDA must update Yutrepia's approved label following Liquidia's settlementLikely
- Liquidia settlement may shift competitive dynamics for BiogenBiogen may face a shifting competitive landscape following Liquidia's settlementPossible
Keep exploring
The entities involved
-
United Therapeutics
biotech company based in Silver Spring, Maryland, United States